These results demonstrate that UHRF1 plays a critical role in KRAS-driven tumorigenesis and may be an attractive drug target for the treatment of KRAS mutant NSCLC and/or other KRAS-driven cancers. This evidence concerns the gene UHRF1 and non-small cell lung carcinoma.